IP13: Penile & Testicular Cancer I
Friday, May 15, 2026 1:00 PM to 3:00 PM · 2 hr. (America/New_York)
145AB
Poster and Podium Sessions
Oncology: Testis/Penis
Friday, May 15
IP13-01: Liquid Biopsy Using Next-Generation Sequencing to Predict Lymph Node Metastases in Penile Squamous Cell Carcinoma
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-02: Single-Cell Transcriptomic Characterization of the Tumor Immune Microenvironment and Heterogeneity Landscape in Penile Cancer
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-03: Survival of the fittest: Outcomes in node positive penile cancer patients where non-surgical management is utilised in place of RILND.
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-04: Real-World Patterns and Predictors of Surgical Lymph-Node Management in Penile Cancer: Insights from the Epic COSMOS Database
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-05: Comparative real-world outcomes of multimodal treatment strategies in patients with locally advanced N3-stage penile cancer: a retrospective cohort study
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-06: Penile Cancer Treatments and Their Psychiatric Sequelae: A National Analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-08: Age-Stratified Association Between Inflammatory Penile Disorders and Penile Cancer: A Tenfold Increased Risk Across All Age Groups
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-09: Prognostic Impact of Recurrence on Survival in Surgically Treated Penile Cancer: A 12-Year Retrospective Cohort (2013–2025)
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-10: Pure testicular seminomas that relapse with nonseminomatous elements: clinical patterns and management
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-11: Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Seminoma: Comparative Analysis Against Established Paradigms Using the National Cancer Data Base
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-12: Primary Retroperitoneal Lymph Node Dissection (RPLND) for clinical stage IIA/IIB Seminoma – Updated Population-Based Results from Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-13: Outcomes of primary retroperitoneal lymph node dissection for clinical stage IIB testicular seminoma: A binational retrospective analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-14: Post-chemotherapy retroperitoneal lymph node dissection for patients with metastatic pure seminoma
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-15: Robotic versus Open Post-Chemotherapy Retroperitoneal Lymph Node Dissection: A Propensity Score Matched Study Across Eleven Academic Medical Centers
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-16: Robotic-Assisted Retroperitoneal Lymph Node Dissection for Metastatic Testicular Malignancies – a 9-Year Comparative Analysis of the Outcomes and Learning Curve
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-17: Robotic Primary and Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: Single Institution Experience
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-18: Beyond a Simple Procedure: Multicenter Evaluation of Surgical Practices in Radical Orchiectomy for Testicular Germ Cell Tumors
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-19: Delayed orchiectomy and retroperitoneal lymph node dissection pathology after chemotherapy: Correlation and prognostic impact in advanced germ cell tumors
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-20: The Role of Delayed Orchiectomy Following Chemotherapy for Metastatic Germ Cell Tumours
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-21: Circulating Tumor DNA Performance in Primary Retroperitoneal Lymph Node Dissection: A Stage-Based Analysis
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-22: Performance of Circulating Tumor DNA as a Biomarker in Testicular Seminoma and Non-seminomatous Germ Cell Tumor
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-23: Tumor-Informed Circulating Tumor DNA for Relapse Detection in Clinical Stage I Testicular Cancer
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-24: Prospective evaluation of the performance of MiR371 test under real-life conditions for the diagnosis of testicular germ cell cancer
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
IP13-26: Dynamics of Circulating miR-371a-3p Levels Before and After BEP Chemotherapy in Patients with Metastatic Seminoma and Non-seminomatous Germ Cell Tumor
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
Olivia Steenbock · University Hospital of Cologne
IP13-27: How reliable are serum tumor markers in the diagnosis of small testicular masses? A multicentric analysis from the Milan Testis Cancer Alliance
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
Christian Corsini · IRCCS Ospedale San Raffaele
IP13-28: Association of Area Deprivation Index with Testicular Cancer Diagnosis and Outcomes in a Contemporary North American Cohort
Friday, May 15, 2026 1:00 PM to 3:00 PM
145AB
Registered attendees
Patrick Michael
FellowNCI/NIH